Ticagrelor Administered as Standard Tablet or Orodispersible Formulation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

Also called NCT03822377

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT03822377
  • EudraCT 2018-001790-25
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03822377. Randomized; single masking; primary purpose treatment. Start 2019-06-27 (actual); primary completion 2020-08-31 (actual). Results posted on 2021-09-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
Acronym
TASTER
Condition
ST Elevation Myocardial Infarction
Condition
NSTEMI - Non-ST Segment Elevation MI
Intervention (Drug)
Ticagrelor orodispersible tablets
Intervention (Drug)
Ticagrelor standard tablets
Lead sponsor
Azienda Ospedaliero Universitaria di Sassari (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct03822377
Content hash
24bace948360710ad78237ca84189f3b4ed54d46fca5423509c311a967472fd3